Xeris Retires All 2028 Convertible Notes via Exchange and Conversion, Issuing 8.6M Shares
XERS sits 81% above its 52-week low of $4.87.
Summary
Xeris retired all remaining 2028 convertible notes through an exchange and conversion, issuing 8.6 million shares and paying $23 million cash. The move eliminates the convertible overhang entirely.
Key Events · Financing and Capital Events · XERS
-
2028 Notes Fully Retired
Xeris completed the exchange of $23M in 2028 convertible notes for ~5.0M shares and $23M cash, and a separate holder converted $10.5M into ~3.6M shares. No 2028 Notes remain outstanding.
-
Dilution Impact
Total shares issued: ~8.6M, representing approximately 5% dilution based on ~172M shares outstanding. The cash portion was funded with on-hand liquidity.
-
Capital Structure Simplification
Retiring the convertible notes removes a potential overhang and future dilution risk, simplifying the balance sheet as the company transitions to sustained profitability.
-
Follow-Through on Prior Announcement
The exchange was initially disclosed on June 11, 2026, with an estimated 4.6M shares; final count increased to 5.0M. The additional conversion was not previously announced.
Analysis · XERS · Life Sciences
Xeris completed the previously announced exchange of $23M in 2028 convertible notes for ~5.0M shares and $23M cash, and a separate holder converted $10.5M into ~3.6M shares. The combined 8.6M shares represent roughly 5% dilution but eliminate the entire 2028 note overhang — removing a potential source of future dilution and simplifying the capital structure. The cash portion was funded with on-hand liquidity, preserving balance sheet strength. This follows a strong Q1 where the company achieved net income and positive operating cash flow, making the debt retirement a deleveraging milestone.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XERS was trading at $8.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.87 to $10.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.